Benefit of veno-arterial extracorporeal membrane oxygenation combined with Impella (ECpella) therapy in acute coronary syndrome with cardiogenic shock

Patients with acute coronary syndrome complicated with cardiogenic shock (ACS-CS) frequently require mechanical circulatory support. In addition to veno-arterial extracorporeal membrane oxygenation (VA-ECMO), use of the Impella® (ECpella) (Abiomed Inc., Danvers, MA, USA) heart pump may improve the p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiology 2022-08, Vol.80 (2), p.116-124
Main Authors: Shibasaki, Ikuko, Masawa, Taito, Abe, Shichiro, Ogawa, Hironaga, Takei, Yusuke, Tezuka, Masahiro, Seki, Masahiro, Kato, Takashi, Watanabe, Ryo, Koshiji, Nobuo, Saitou, Shunsuke, Ogata, Kouji, Haruyama, Yasuo, Toyoda, Shigeru, Fukuda, Hirotsugu
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - complications
Acute Coronary Syndrome - therapy
Acute coronary syndromes
Cardiogenic shock
Extracorporeal Membrane Oxygenation - adverse effects
Heart-Assist Devices - adverse effects
Humans
Impella
Intra-Aortic Balloon Pumping - adverse effects
Intraaortic balloon pumping
Retrospective Studies
Shock, Cardiogenic - etiology
Shock, Cardiogenic - therapy
Treatment Outcome
Veno-arterial extracorporeal membrane oxygenation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with acute coronary syndrome complicated with cardiogenic shock (ACS-CS) frequently require mechanical circulatory support. In addition to veno-arterial extracorporeal membrane oxygenation (VA-ECMO), use of the Impella® (ECpella) (Abiomed Inc., Danvers, MA, USA) heart pump may improve the prognosis of such patients. In this study, we compared the efficacy of VA-ECMO plus intra-aortic balloon pumping (ECMO-IABP) with that of the ECpella for add-on circulatory support of VA-ECMO. Clinical outcomes of 64 patients with ACS-CS treated with ECMO-IABP (n = 41) or ECpella (n = 23) between January 2013 and April 2021 were retrospectively analyzed. The primary outcomes were 30-day and 365-day mortality. In addition, patients resuscitated after cardiopulmonary arrest (CPA) were evaluated separately. The ECpella group showed significantly lower mid-term mortality than the ECMO-IABP group [30-day mortality (39.1% vs 56.1%, respectively; p = 0.193) and 365-day mortality (43.5% vs 75.6%, respectively; p = 0.010)], with significantly higher rates of new hemodialysis and bleeding at the vascular access site. Also, among the limited number of patients resuscitated from CPA, mortality was significantly lower in the ECpella group than the ECMO-IABP group [30-day mortality (28.6% vs 65.4%, respectively; p = 0.026) and 365-day mortality (28.6% vs 84.6%, respectively; p 
ISSN:0914-5087
1876-4738
DOI:10.1016/j.jjcc.2022.02.013